Compare Novo Nordisk A/S (NVO) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs SkyWest Inc — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while SkyWest Inc trades at $96.52 (market cap $3.75B). The key difference: Novo Nordisk A/S is far larger — about 44.1× SkyWest Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and SkyWest Inc for 8 Days on average.
| NVO | SKYW | |
|---|---|---|
Market Cap | $165.31B | $3.75B |
Volume | 11,432,838 | 196,324 |
Sector | Health | Industrials |
52-Week High | $63.98 | $115.94 |
52-Week Low | $35.29 | $78.40 |
Typical Hold Time | 116 Days | 8 Days |
Enterprise Value | $179.56B | $5.54B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
SkyWest (SKYW) trades at $96.73, up 0.09% on the day, with a bearish technical signal but strong fundamentals including a P/E of 9.6 and net income margin of 9.78%. Recent earnings show mixed results, with a Q1 2026 beat but a Q2 2026 miss. The company is expanding its fleet and flying agreements, supporting growth amid cost pressures.
The outlook is cautiously optimistic, with a consensus price target of $112 offering 16% upside. Risks include execution on cost control and competitive pressures, but low valuation and analyst buy ratings suggest potential for recovery if operational trends improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
